Patients with diabetes or obesity receiving GLP-1 RAs are unlikely to experience an increase in the already low rates of ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Continuing GLP-1 RA use through surgery increases risk for surgical complications including aspiration and conversion to intubation ...

Investigating GLP-1 RAs reveals their impact on women's health, addressing metabolic disorders, reproductive health, and ...

A coalition of over 20 leading health organizations is calling on the U.S. Food & Drug Administration (FDA) to enforce ...

Spending growth for simple medications used to treat common health problems is outstripping spending growth for pricey medications used to treat complex and chronic conditions, according to a new ...

HealthDay News — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with better graft and patient survival among kidney transplant recipients with diabetes, according to a study ...

At STAT's Breakthrough Summit East, the CEOs of Ro and Included Health said the the U.S. health care system poses obstacles ...

are taking GLP-1 — glucagon-like peptide-1 — receptor agonists, medications that were initially developed and FDA-approved to treat Type 2 diabetes are also being used off-label for weight ...

According to a study published in JAMA Network Open, among patients with type 2 diabetes (T2D), the use of glucagon-like ...

Because obesity and obesity-related conditions have been linked to several types of cancer, doctors believe that these ...